论文部分内容阅读
本工作进行了治疗用 Na131I胶囊的研制及其性能评价。首先通过对失去不同结晶水及不同直径的 Na2 HPO4 · 12 H2 O吸附条件的研究得出 :失结晶水越多 ,吸附量越大 ;晶体颗粒越小 ,吸附量越大。 50 0 mg直径小于 0 .135mm的无水 Na2 HPO4 在 0号胶囊中可吸附 2 70 μL 0 .0 5mol/ L Na OH溶液。吸附剂中加入 1%的 Vc,可减少 131I的损失。胶囊的完全崩解时间为 5min,在 30 d内 2 0个样品的放射性都在平均值的 96.5%～ 10 3.5% ;样品的放射化学纯度 >95% ,核纯度 >99% ,均匀度和稳定性良好。动物实验结果表明 ,该胶囊无异常毒性 ;家兔甲状腺对治疗剂量的 Na131I胶囊和 Na131I液体在各时相的摄取率无差异。
This work was carried out for the treatment of Na131I capsule and its performance evaluation. First of all, through the study on the adsorption conditions of Na2 HPO4 · 12 H 2 O with different crystal water and different diameters, it is found that the more the water is lost, the larger the adsorption capacity; the smaller the crystal particles, the larger the adsorption capacity. 50 0 mg Anhydrous Na2 HPO4 less than 0.135 mm in diameter can absorb 2 70 μL of 0 · 0 5 mol / L NaOH solution in size 0 capsule. Adsorbent added 1% Vc, can reduce the loss of 131I. The complete disintegration time of the capsule was 5 min, and the radioactivity of 20 samples was 96.5% ~ 10 3.5% of the average value within 30 days. The radiochemical purity of the sample was> 95%, the purity of the nucleus was> 99%, evenness and stability Good sex. The results of animal experiments show that the capsule has no abnormal toxicity; there is no difference in the uptake rate of Na131I capsule and Na131I liquid in rabbits thyroid gland at each time phase.